From Evidence to Action: What Clinicians Can Do to Transform Cholesterol Care

The convergence of the 2026 ACC/AHA guideline update, the VESALIUS-CV primary prevention findings, and the Ez-PAVE treat-to-target evidence creates an unusually coherent and actionable message for clinicians: lower LDL, achieved sooner and sustained longer, reduces cardiovascular events across the entire spectrum of risk.

For busy clinicians, the first practical step is knowing the targets. For very high-risk patients with established ASCVD, the goal is LDL below 55 mg/dL and apolipoprotein B below 55 mg/dL. For patients with diabetes plus risk factors or those with ASCVD not at very high risk, both targets are below 70 mg/dL. For high-risk primary prevention, LDL below 100 mg/dL and apolipoprotein B below 90 mg/dL. The inclusion of apolipoprotein B targets is important, as this measure captures all atherogenic particles—including lipoprotein(a) and triglyceride-rich remnants—particularly relevant in patients with diabetes or metabolic syndrome. At least one lifetime lipoprotein(a) measurement is also recommended for all adults.

Translating this evidence into practice requires systemic change. The data on clinical inertia are sobering, but the solutions are within reach. Team-based care models—engaging pharmacists, nurses, and prior authorization specialists to co-manage intensification—have demonstrated success. EHR systems that auto-calculate PREVENT scores and flag undertreated patients can reduce the cognitive burden on individual clinicians. And payer policies that streamline access to PCSK9 inhibitors and newer non-statin agents are essential for equitable goal attainment. Throughout all of this, lifestyle remains the class I foundation: smoking cessation, 150 or more minutes per week of moderate-intensity physical activity, and a diet rich in fruits, vegetables, whole grains, and lean proteins are the bedrock on which pharmacotherapy is built.